

Article

Not peer-reviewed version

Clinical Profiles in Multiple Sclerosis: Cognitive Reserve and Motor Impairment Along Disease Duration

Sabrina Maffezzini , <u>Veronica Pucci</u> , Alice Riccardi , Sonia Montemurro , Marco Puthenparampil , Paola Perini , Francesca Rinaldi , Paolo Gallo , Giorgio Arcara , <u>Sara Mondini</u> *

Posted Date: 29 June 2023

doi: 10.20944/preprints202306.2127.v1

Keywords: Multiple sclerosis; Cognitive impairment; Motor impairment; Disease duration; Cognitive reserve; Generalized Additive Models



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

Clinical profiles in Multiple Sclerosis: Cognitive Reserve and motor impairment along disease duration

Sabrina Maffezzini¹, Veronica Pucci ^{2,3}, Alice Riccardi¹, Sonia Montemurro⁴, Marco Puthenparampil¹, Paola Perini¹, Francesca Rinaldi¹, Paolo Gallo¹, Giorgio Arcara⁴, Sara Mondini^{2,3*}

- ¹ Multiple Sclerosis Centre, Department of Neuroscience, University-Hospital of Padua;
- ² Department of Philosophy, Sociology, Education and Applied Psychology, University of Padua
- ³ Human Inspired Technology Centre (HIT), University of Padua
- ⁴ IRCCS San Camillo Hospital, Venice, Italy
- * Correspondence: sara.mondini@unipd.it; Tel.: 00390498276641

Abstract: (1) Background. Cognitive impairment in people with Multiple Sclerosis (MS) has been studied in relation to some clinical variables (e.g., motor disability and disease duration) and lifestyle factors such as Cognitive Reserve (CR). However, only very few studies have considered the interaction of clinical variables and cognitive reserve in preserving the integrity of the neuropsychological profile. In this paper, we hypothesised that a higher level of CR might predict good cognitive efficiency by modulating the clinical outcome of the disease. (2) Methods. A sample of 100 participants with MS (age range 30-74), was recruited and assessed remotely with a questionnaire to measure CR and a cognitive screening test. Data were analysed through Generalized Additive Models. (3) Results. We found that the model analysing the interaction between CR and disease duration, and between CR and motor disability was able to explain a significant percentage of cognitive performance. In particular, higher levels of CR predicted better cognitive performance despite long disease duration, unless the motor disability was severe. (4) Conclusion. This study highlights the crucial role of CR in modulating cognitive efficiency in people with MS.

Keywords: Multiple sclerosis; Cognitive impairment; Motor impairment; Disease duration; Cognitive reserve; Generalized Additive Models

1. Introduction

Multiple Sclerosis (MS) is a chronic, inflammatory, degenerative disease affecting both grey and white matter of the Central Nervous System [1]. Cognitive impairment occurs in up to 70% of individuals with MS [2, 3, 4], who typically show affected cognitive functioning in the domains of sustained attention, information processing speed, memory, and executive functions [5, 6, 7].

Although cognitive impairment is one of the most frequent symptoms of MS, it is unclear why some patients do not show such dysfunctions [8, 9], which usually appear in older individuals [10] and in those with a longer history of disease (i.e., disease duration) [11]. Recent longitudinal studies showed that higher motor disability, measured on the Expanded Disability Status Scale (EDSS) [12], is correlated with lower cognitive functioning [13, 14], even if the relationship between motor and cognitive impairment is still controversial [15].

Recently, Cognitive Reserve (CR) has been considered a construct able to explain a possible variance of cognitive impairment in individuals with MS [16, 17], similarly to what it does in healthy older populations at risk of dementia [18]. CR allows to sustain cognitive performance when individuals have to face age-related changes, brain damage or disease [19, 20, 21]). CR derives from lifetime experiences, intellectual activity, and environmental factors, all things that allow individuals to maintain good cognitive efficiency [22]. Several proxies are used to quantify CR: education, occupational attainment, engagement in leisure and social activities, IQ and vocabulary size [23, 24]. One of the

most used tools to quantify CR, in a standardised way, is the Cognitive Reserve Index questionnaire (CRIq) [25].

Some studies have examined the role of CR in modulating cognitive functioning in individuals with MS [26, 27]. In general, results of such studies have shown that high levels of CR may be associated with less cognitive dysfunction [28, 29, 30]. Instead, together with old age, low levels of CR are one of the most significant predictors of cognitive decline in MS [31, 32].

However, only few studies have focused on the role of CR in the cognition of individuals with MS while also considering clinical indices such as disease duration, age of onset, level of motor disability. Rimkus et al. (2018) [33] suggested that the protective effect of CR is strongest in the early years after disease onset when there is a reduced effect of inflammatory activity on cognition. A meta-analysis [28] has highlighted the only effect of CR on cognitive performance and not on other clinical variables such as disease severity, disease duration, motor disability (measured with EDSS) and type of MS. Furthermore, Artemiadis et al. (2020) [34] underlined that in individuals with the same level of motor disability, those with higher CR showed better cognitive performance.

These findings, however, are controversial and further investigation is needed. Indeed, CR was quantified through a heterogeneous pool of proxies and, in most cases, without a composite index. Tremblay et al.'s (2023) [35] investigation considered a composite measure of CR using the standardised and reliable Cognitive Reserve Index questionnaire (CRIq) [25]. The Authors found that CR moderated the relationship between EDSS and cognition, but they did not take into account disease duration.

The purpose of the present investigation is to verify whether a higher level of CR may interact with disease duration and motor disability in predicting cognitive outcomes. In particular, we hypothesised that, despite disease duration and motor impairment, a higher level of CR (quantified with the CRIq) may allow individuals with MS to maintain good cognitive efficiency. Due to the multiple factors considered in our hypothesis, we analysed the data through the Generalized Additive Models (GAMs) [36], a statistical approach which allowed us to verify the complex interaction among multiple continuous variables.

2. Materials and Methods

2.1. Participants

In this cross-sectional study, 100 individuals with MS were enrolled, 88 with Relapsing-Remitting MS and 12 with progressive MS (according to the recent guidelines by Lublin et al., 2015) [37]. Participants' (72 F and 28 M, F: M=2.6:1) mean age was 50.9±9.25 (range 30-74), mean education was 12.5±3.53 years (range 5-21), disease duration ranged from 1 to 37 years (mean=14.82±9.28) and motor disability, measured through EDSS, ranged from 1.0 to 8.0 (mean=3±1.89). Most participants were treated with first- or second-line drugs, whereas 7% of them had no pharmacological therapy for a number of reasons (e.g., personal choice, no availability of appropriate drugs for the typology of MS).

Inclusion criteria were: (i) age >18, (ii) no history/evidence of psychiatric or neurological disorders other than Multiple Sclerosis, (iii) no history of alcohol or drug abuse, (iv) no hearing difficulties, (v) Italian mother tongue.

2.2. Procedure

Participants were recruited between January and July 2021 at the Multiple Sclerosis Centre of the University Hospital of Padua, where they arrived for diagnosis or for clinical follow-ups. The entire procedure of this study was conducted remotely, by telephone. Each participant was informed about the research purpose and their consent was acquired via audio-recording. The examiner ensured that the room was quiet and distraction-free and that the telephone connection was stable.

All participants first answered the Cognitive Reserve Index questionnaire (CRIq) [25] and then underwent the Tele-Global Examination of Mental State, version A (Tele-GEMS) [38]. The whole administration lasted about 20 minutes.

The study was approved by the Ethical Committee of the Hospital of Padua (Prot. N 19669) and it was conducted in accordance with the Declaration of Helsinki.

2.3. Assessment and materials

For each participant, Clinical variables, Cognitive reserve, and Neuropsychological measures were collected.

Clinical variables: included 1) Disease Duration (in years) registered in the clinical report, and personal anamnesis; 2) Motor disability, assessed through EDSS [12] administered by trained neurologists. The other two tools were administered by a trained psychologist.

Cognitive Reserve: measured on the Cognitive Reserve Index Questionnaire (CRIq) [25], which is a semi-structured interview to quantify a person's CR considering education (CRI-Education), working activity (CRI-WorkingActivity), and leisure time activities (CRI-LeisureTime) carried out during adulthood. The administration of CRIq provides the Index of cognitive reserve (CRI). A full description of the 20 items included in the CRIq and instructions for its administration are available on https://www.cognitivereserveindex.org/.

Neuropsychological assessment. Cognitive functioning was assessed through Tele-Global Examination of Mental State (Tele-GEMS) [38], a new cognitive screening tool that is administered remotely and consists of ten tasks investigating different cognitive domains: orientation, memory, working memory, spatial representation, language, auditory attention, verbal fluency, and pragmatic abilities. It provides an index of global cognitive functioning, which reflects the balanced contribution of each task to a total score that ranges from 0 to 100. The administration lasts about 10 minutes. Instructions, score sheets, and cut-offs according to age, education, and CR are available at https://osf.io/r3ta5/.

2.4. Statistical Analysis

All statistical analyses were performed with R software [39]. First, an independent sample t-test was carried out to analyse possible differences according to sex to verify whether to include this variable in the subsequent analyses. Descriptive correlation analyses among our predictors were calculated through Pearson's r. Generalized Additive Models (GAMs) [36] of increasing complexity were used to investigate the interaction between clinical variables (i.e., EDSS and Disease Duration) and cognitive reserve (CRI) on the one side, and cognitive functioning (Tele-GEMS) on the other. Notably, GAMs are more flexible than the general linear models, allowing to test non-linear relationships between the independent and dependent variables. GAMs can also manipulate complex data, and their visualisation can help to understand the relationship between variables. In our analyses, the models were built from simpler to more complex in order to examine the best pattern of variables that would fit our data. The goodness of the models was assessed with Akaike Information Criterion (AICc) and GCV was used to check for any possible overfitting (GCV) [40, 41]. We also calculated the Akaike Information Criterion Weights (AICw) which is the probability of a model being the best among a given set of models and, as such, it can be used for model selection. The best model was chosen according to AICw (R2 and AIC are also reported) and a series of diagnostic tests were carried out to check the appropriateness of model characteristics. We also checked the quality of GAM models by visual inspection of the residuals.

3. Results

Descriptive statistics of our variables are reported in Table 1.

Table 1. Descriptive statistics of the sample of the study.

	Mean	SD	Median	Min	Max	Kurtosis	Skewness	Q1	Q3
Age	50.89	9.25	51	30	74	0.09	0.04	46	56
Education	12.53	3.53	13	5	21	-0.65	0.04	8	13

Disease Duration	14.82	9.28	13	1	37	-0.75	0.45	7	21
EDSS	3.04	1.90	2.50	1	8	-0.31	0.86	1.5	4
CRI	105.67	13.58	104	78	142	-0.29	0.33	96	115
Tele-GEMS	76.74	15.65	81.8	19.5	98.3	1.78	-1.31	60.08	87.73

Note. EDSS = Expanded Disability Status Scale [12]; CRI = Cognitive Reserve Index [25].

Our sample did not show any difference between males and females on Tele-GEMS performance (t(98)=-0.79, p=0.43); thus, sex was not included as a predictor in GAM models.

Correlational analyses showed that Tele-GEMS correlated positively with CRI (r=0.50, p<0.001) and negatively with Age (r=-0.29, p=0.003), EDSS (r=-0.44, p<0.001) and Disease Duration (r=-0.23, p=0.02). Correlations among all our variables of interest (Tele-GEMS, CRI, Age, EDSS and Disease Duration) are reported in Table 2.

Table 2. Correlation matrix between the variables of interest.

Variable	1	2	3	4	5
1. Age	-				
2. Disease Duration	0.34	-			
3. EDSS	0.30	0.36	-		
4. CRI	0.13	0.05	-0.36	-	
5. Tele-GEMS	-0.29	-0.23	-0.44	0.50	-

Note. EDSS = Expanded Disability Status Scale [12]; CRI = Cognitive Reserve Index [25].

Generalized Additive Models analyses (GAMs) underlined that the best Model was the one having Age, CRI, EDSS, Disease Duration as covariates and including the interaction between CRI and EDSS and CRI and Disease Duration (Model 4). In particular, Model 4 had the highest R^2 ($R^2 = 0.458$ and 50.9% Deviance explained) and the lowest AIC. We chose Model 4 as it was the best according to AICw (See Table 3). A series of diagnostic tests (R function 'gam.check') showed appropriate characteristics for the tensors (for CRI*Disease Duration: k'=4, p=0.78; for CRI*EDSS: k'=4, p=0.99).

Table 3. Results of Generalized Additive Models with Tele-GEMS as the dependent variable and Age, CRI, Disease Duration, EDSS as covariates, CRI and Disease Duration and CRI and EDSS in interaction. The table shows, for the four GAMs carried out, the result associated with the Intercept, the Smooth Terms and the Model Fit. Within the Intercept, the table shows: standard error, *t*-value and *p*-value associated with the standard error. Within the Smooth Terms, the table reports: names of smooth terms, estimated degrees of freedom (Edf), F-value and *p*-value associated with the smooth terms. Within the Model Fit, the table shows: R-squared with the percentage of deviance explained, the AIC and the model weights which represents the probability of a model to be the best among the given set of models.

Generalized Additive Models: Interaction between Cognitive Reserve, Disease Duration and EDSS

Tele-GEMS = Dependent Variable


Mode	Intercept			Smooth Terms				Model Fit			
Mode 1	Esti- mate (Stand ard er- ror)	t	p	Terms	Edf	F	р	\mathbb{R}^2	Dev	AIC	Model weight s

			<.00	s(Age)	1	3.4 9	0.06 5														
1	76.74	64.7		s(CRI)	3.8 7	8.5 6	<.00 1	0.4	46.5 %	787.9 6	0.100										
1	(1.19)	1	1	s(DD)	1	1.5 4	0.21 7	3													
			s(EDSS)	1	1.8 2	0.18															
				s(Age)	1	2.7 1	0.10 3														
2 76.67 64.7 (1.18) 1		s(CRI)	3.9 4	7.6 7	<.00 1	-															
		<.00 1	s(DD)	1	1.6 4	0.20 3	0.4	49.5 %	786.8 6	0.183											
				s(EDSS)	1.2 9	0.7 4	0.33 7	•													
					ti(CRI,DD)	1.9 3	1.4 1	0.25 7	•												
		57.5 9	<.00 1	s(Age)	1	3.7 1	0.56 7			788.4 3	0.079										
				s(CRI)	4.1 3	8.1	<.00 1	-	47.6 %												
3	76.13 (1.32)			s(DD)	1	1.9 4	0.16 7	0.4													
														s(EDSS)	1	2.5 4	0.11 4	-			
				ti(CRI,EDSS	1	1.0 5	0.30 7	-													
			<.00 1	s(Age)	1	3.3 7	0.07														
75.0	75.05	55.0		s(CRI)	4.2 7	8.5 5	<.00 1	0.4	50.9 %	784.2	0.420										
4	(1.36)	3		s(DD)	1	2.4 7	0.12			6	0.638										
				s(EDSS)	1	2.7 9	0.09	<u>-</u>													

ti(CRI,DD)	1	5.7 0	0.01 9	
ti(CRI,EDSS	1	4.9 8	0.02 8	

A visual inspection of Model 4 related to the interaction between CRI and Disease Duration is shown in Figure 1, and related to the interaction between CRI and EDSS in Figure 2. These two Figures give additional information on the interaction between CR EDSS and Disease Duration in predicting cognitive performance (i.e., Tele-GEMS). Tele-GEMS scores are represented with different colours: the darker shades of blue in the contour plot represent lower scores, while the darker shades of yellow represent higher scores. Figure 1 shows the interaction between CRI and Disease Duration, highlighting that high levels of CRI (on the x-axis) are associated with better Tele-GEMS (on the y-axis) even when the Disease Duration (on the z-axis) is very high. However, a negative effect of Disease Duration is found on Tele-GEMS in persons with low CR. Figure 2 shows the interaction between CRI and EDSS, indicating that high levels of CRI (on the x-axis) correspond to higher Tele-GEMS (on the y-axis), but that such a positive effect of CRI is significantly attenuated when EDSS (on the z-axis) is very high (i.e., severe motor disability). This is clear in Figure 2 (right side) in correspondence of the dark blue in the upper right-hand side corner. In the case of low CR, instead, Tele-GEMS is low at any level of EDSS.

CRI and Disease Duration of MS on Cognitive Performance



CRI and Disease Duration of MS on Cognitive Performance





Figure 1. Interaction effect of CRI and Disease Duration on Tele-GEMS. The figure shows the effect of the tensor surface associated with the interaction between CRI and Disease Duration (in three-dimensional mode on the left side and in two-dimensional mode on the right side). CRI is on the x-axis, Disease Duration is on the y-axis, and Tele-GEMS is on the z-axis in the left side and is represented by the red lines in the right side. The darker blue in the contour plots shows lower Tele-GEMS, whereas darker shades of yellow show higher Tele-GEMS.

CRI and Disease Duration of MS on Cognitive Performance



CRI and clinical Severity of MS on Cognitive Performance




Figure 2. Interaction effect of CRI and EDSS on Tele-GEMS. The figure shows the effect of the tensor surface associated with the interaction between CRI and EDSS (in three-dimensional mode on the left side and in two-dimensional mode on the right side). CRI is on the x-axis, EDSS is on the y-axis, and Tele-GEMS is on the z-axis in the left side and is represented by the red lines in the right side. The darker blue in the contour plots shows lower Tele-GEMS, whereas darker yellow shows higher Tele-GEMS.

4. Discussion

The present study aimed to investigate the impact of factors such as CR, disease duration and motor disability on the cognitive efficiency of people with Multiple Sclerosis. It is known that high levels of CR are associated with better cognitive performance in both healthy [42] and pathological people, such as those who have dementia [43] or MS [30]. Our data, obtained with a sample of 100 people with MS, confirmed what is reported in the literature [11, 14]: cognitive efficiency is negatively correlated with disease duration and with motor disability, but positively correlated with CR.

The added value of the present study is the methodological approach adopted. Indeed, the use of GAMs [36] allowed us to consider the potentially complex interaction between different clinical variables and socio-demographic variables, at the same time disentangling their respective effects. In the present study, motor disability and disease duration in interaction with CR and age were

considered as predictors of cognitive performance. In the literature, these same variables are rarely considered together in interaction. Our results confirm the positive effect of CR in predicting a better cognitive profile regardless of disease duration and motor disability, but not in the case of severe motor impairment (i.e., EDSS= 6-7, corresponding to needed bilateral assistance to walk 100 m.). This is in contrast with a recent paper [33] whose results confined a positive effect of CR to the first five years of the disease. Further research is needed to clarify how CR may modulate cognitive performance in individuals with MS at different stages of the disease. As MS is a degenerative disorder, our findings (i.e., an extended positive effect of CR throughout the disease) are crucial, since they suggest that patients with high CR may maintain a suitable quality of life for longer. However, at a high level of motor impairment CR is no longer protective and, at this point of the disease, a cognitive decline appears inevitable. In line with our results, Tremblay et al.'s (2023) [35] research highlighted the modulating effect of CR on motor disability and underlined its effect on specific cognitive domains (i.e., visuospatial memory and processing speed); however, they had not considered disease duration, which we found is an important clinical variable.

In this context, Amato et al. (2019) [31] reported similar conclusions, but on child and adolescent patients with MS. In their research, they found a positive relationship between physical activity and CR in predicting cognitive performance, a relationship that has been gaining more and more attention in the context of CR [44, 45]. These findings suggest the potential benefits of training focused on both cognitive and physical activities in enhancing CR and, consequently, reducing possible decline.

This cross-sectional investigation is not, however, exempt from limitations. First of all, MS is a progressive disorder and any possible effect of CR over time should be further investigated through longitudinal observations, in which the clinical changes in MS patients would be systematically monitored. Secondly, neuroimaging data were not available for this study. However, if on the one hand the use of such data would have allowed us to better characterise brain deterioration, on the other, GAMs provided a solid pool of information accounting for the complex interaction among different clinical variables.

Other important factors possibly at play in determining cognitive efficiency in our sample would be perceived fatigue, type of medication, mood deflection and other psychological traits. These characteristics have not been considered in the present study and further investigation would prove helpful to examine the interaction between CR and clinical MS manifestations.

5. Conclusions

In conclusion, this study reveals that accounting for the interplay between CR and disease duration, as well as between CR and motor disability, may explain a significant degree of variance in cognitive performance. Our results, which we hope will be of use to clinicians and researchers, indicate that high levels of CR are related to improved cognitive performance even in prolonged disease duration, although severe motor disability may, at some point, attenuate this "protective effect".

Author Contributions: Conceptualization, Sa. Mo., and A.R; methodology, So.Mo., G.A., and V.P., formal analysis, So.Mo., G.A., and V.P.; investigation, Sa. Ma., data curation, Sa.Ma. and V.P.; writing—original draft preparation Sa.Mo., V.P., and Sa.Ma.; writing—review and editing, all authors; visualization, So.Mo. and G.A., supervision, Sa.Mo and P.G.; All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Hospital of Padua (Prot. N 19669).

Informed Consent Statement: Informed consent was obtained from all patients involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author under a reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dobson, R., Giovannoni, G. Multiple sclerosis - a review. Eur J Neurol 2019, 26(1), 27–40.

- Oreja-Guevara, C., Ayuso Blanco, T., Brieva Ruiz, L., Hernández Pérez, M.A., Meca-Lallana, V., Ramió-Torrentà, L. Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Front neurol 2019, 10, 581.
- 3. Sumowski, J.F., Benedict, R., Enzinger, C., Filippi, M., Geurts, J.J., Hamalainen, P., Hulst, H., Inglese, M., Leavitt, V.M., Rocca, M.A., Rosti-Otajarvi, E.M., Rao, S. Cognition in multiple sclerosis: State of the field and priorities for the future. *Neurol* **2018**, *90*(*6*), 278–288.
- Chiaravalloti, N.D., DeLuca, J. Cognitive impairment in multiple sclerosis. *Lancet Neurol* 2008, 7(12), 1139– 1151.
- 5. Benedict, R.H.B., Amato, M.P., DeLuca, J., Geurts, J.J.G. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. *Lancet Neurol* **2020**, *19*(10), 860–871.
- 6. Grzegorski, T., Losy, J. Cognitive impairment in multiple sclerosis a review of current knowledge and recent research. *Rev Neurosci* **2017**, *28*(*8*), 845–860.
- 7. Rocca, M.A., Amato, M.P., De Stefano, N., Enzinger, C., Geurts, J.J., Penner, I.K., Rovira, A., Sumowski, J.F., Valsasina, P., Filippi, M., MAGNIMS Study Group. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. *Lancet Neurol* **2015**, *14*(3), 302–317.
- 8. Ghaffar, O., Fiati, M., Feinstein, A. Occupational attainment as a marker of cognitive reserve in multiple sclerosis. *PloSone* **2012**, *7*(10), e47206.
- 9. Benedict, R. H., Zivadinov, R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. *Nat Rev Neurol* **2011**, *7*(6), 332–342.
- 10. Brochet, B., Ruet, A. Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes. *Front neurol* **2019**, *10*, 261.
- 11. Tremblay, A., Charest, K., Brando, E., Roger, E., Duquette, P., Rouleau, I. The effects of aging and disease duration on cognition in multiple sclerosis. *Brain Cog* **2020**, *146*, 105650.
- 12. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurol* **1983**, *33*(11), 1444–1452.
- 13. Yigit, P., Acikgoz, A., Mehdiyev, Z., Dayi, A., Ozakbas, S. The relationship between cognition, depression, fatigue, and disability in patients with multiple sclerosis. *Ir J Med Sci* **2021**, *190*(3), 1129–1136.
- 14. Heled, E., Aloni, R., Achiron, A. Cognitive functions and disability progression in relapsing-remitting multiple sclerosis: A longitudinal study. *Appl neuropsychol. Adult* **2021**, *28*(2), 210–219.
- 15. Amato, M.P., Portaccio, E., Goretti, B., Zipoli, V., Iudice, A., Della Pina, D., Malentacchi, G., Sabatini, S., Annunziata, P., Falcini, M., Mazzoni, M., Mortilla, M., Fonda, C., De Stefano, N., TuSCIMS Study Group. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. *Mult scler J* **2010**, *16*(*12*), 1474–1482.
- Martins Da Silva, A., Cavaco, S., Moreira, I., Bettencourt, A., Santos, E., Pinto, C., Gonçalves, A., Coutinho, E., Samões, R., Dias, C.C., Teixeira-Pinto, A., Da Silva, B.M., Montalban, X. Cognitive reserve in multiple sclerosis: Protective effects of education. *Mult scler J* 2015, 21(10), 1312–1321.
- 17. Amato, M.P., Razzolini, L., Goretti, B., Stromillo, M.L., Rossi, F., Giorgio, A., Hakiki, B., Giannini, M., Pastò, L., Portaccio, E., De Stefano, N. Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. *Neurol* **2015**, *80*(19), 1728–1733.
- 18. Mondini, S., Pucci, V., Montemurro, S., Rumiati, R.I. Protective factors for subjective cognitive decline individuals: trajectories and changes in a longitudinal study with Italian elderly. *Eur J Neurol* **2022**, 29(3), 691–697.
- 19. Stern, Y., Arenaza-Urquijo, E.M., Bartrés-Faz, D., Belleville, S., Cantilon, M., Chetelat, G., Ewers, M., Franzmeier, N., Kempermann, G., Kremen, W.S., Okonkwo, O., Scarmeas, N., Soldan, A., Udeh-Momoh, C., Valenzuela, M., Vemuri, P., Vuoksimaa, E., the Reserve, Resilience and Protective Factors PIA Empirical Definitions and Conceptual Frameworks Workgroup. Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance. *Alzheimers dement: the journal of the Alzheimer's Association* **2020**, *16*(9), 1305–1311
- 20. Pettigrew, C., Soldan, A. Defining Cognitive Reserve and Implications for Cognitive Aging. *Curr Neurol Neurosci Rep* **2019**, *19*(1), 1.
- 21. Barulli, D., Stern, Y. Efficiency, capacity, compensation, maintenance, plasticity: emerging concepts in cognitive reserve. *Trends cog sci* **2013**, *17*(*10*), 502–509.
- 22. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. *J Int Neuropsycol Soc* **2002**, *8*(3), 448–460.

- 23. Grotz, C., Seron, X., Van Wissen, M., Adam, S. How should proxies of cognitive reserve be evaluated in a population of healthy older adults?. *Int psychogeriatr* **2017**, *29*(1), 123–136.
- 24. Harrison, S.L., Sajjad, A., Bramer, W.M., Ikram, M.A., Tiemeier, H., Stephan, B.C. Exploring strategies to operationalize cognitive reserve: A systematic review of reviews. *J clin exp neuropsychol* **2015**, *37*(3), 253–264.
- 25. Nucci, M., Mapelli, D., Mondini, S. Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve. *Aging clin exp res* **2012**, 24(3), 218–226.
- 26. Luerding, R., Gebel, S., Gebel, E.M., Schwab-Malek, S., Weissert, R. Influence of Formal Education on Cognitive Reserve in Patients with Multiple Sclerosis. *Front neurol* **2016**, 7, 46.
- 27. Sumowski, J.F., Rocca, M.A., Leavitt, V.M., Riccitelli, G., Meani, A., Comi, G., Filippi, M. Reading, writing, and reserve: Literacy activities are linked to hippocampal volume and memory in multiple sclerosis. *Mult scler J* 2016, 22(12), 1621–1625.
- 28. Santangelo, G., Altieri, M., Enzinger, C., Gallo, A., Trojano, L. Cognitive reserve and neuropsychological performance in multiple sclerosis: A meta-analysis. *Neuropsychol* **2019**, *33*(3), *379*–390.
- 29. Ifantopoulou, P., Artemiadis, A. K., Bakirtzis, C., Zekiou, K., Papadopoulos, T.S., Diakogiannis, I., Hadjigeorgiou, G., Grigoriadis, N., Orologas, A. Cognitive and brain reserve in multiple sclerosis--A cross-sectional study. *Mul scler relat disord* **2019**, 35, 128–134.
- 30. Sumowski, J.F., Leavitt, V.M. Cognitive reserve in multiple sclerosis. Mult scler J 2013, 19(9), 1122-1127.
- 31. Amato, M.P., Prestipino, E., Bellinvia, A., Niccolai, C., Razzolini, L., Pastò, L., Fratangelo, R., Tudisco, L., Fonderico, M., Mattiolo, P.L., Goretti, B., Zimatore, G.B., Losignore, N.A., Portaccio, E., Lolli, F. Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors. *PloSone* **2019**, *14*(10), e0222929.
- 32. Nunnari, D., De Cola, M.C., Costa, A., Rifici, C., Bramanti, P., Marino, S. Exploring cognitive reserve in multiple sclerosis: New findings from a cross-sectional study. *J clin exp neuropsychol* **2016**, *38*(10), 1158–1167.
- 33. Rimkus, C.M., Avolio, I.M.B., Miotto, E.C., Pereira, S.A., Mendes, M.F., Callegaro, D., Leite, C.D.C. The protective effects of high-education levels on cognition in different stages of multiple sclerosis. *Mult scler relat disord* **2018**, 22, 41–48.
- 34. Artemiadis, A., Bakirtzis, C., Ifantopoulou, P., Zis, P., Bargiotas, P., Grigoriadis, N., Hadjigeorgiou, G. The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients. *Mult scler relat disord* **2020**, *41*, 102047.
- 35. Trembley, A., Charest, K., Brando, E., Roger, E., Duquette, P., Rouleau, I. Cognitive reserve as a moderating factor between EDSS and cognition in multiple sclerosis. *Mult scler relat disord* **2023**, *70*, 104482.
- 36. Wood, S.N. Generalized additive models: An introduction with R, second edition **2017**. In Generalized Additive Models: An Introduction with R, Second Edition.
- 37. Lublin, F.D., Reingold, S.C., Cohen, J.A., Cutter, G.R., Sørensen, P.S., Thompson, A.J., Wolinsky, J.S., Balcer, L.J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P.A., Clanet, M., Comi, G., Fox, R.J., Freedman, M.S., Goodman, A.D., Inglese, M., Kappos, L., Kieseier, B.C., ... Polman, C.H. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurol* 2014, *83*(3), 278–286.
- 38. Montemurro, S., Mondini, S., Pucci, V., Durante, G., Riccardi, A., Maffezzini, S., Scialpi, G., Signorini, M., Arcara, G. Tele-Global Examination of Mental State (Tele-GEMS): an open tool for the remote neuropsychological screening. *Neurol sci* **2023**, 1–10.
- 39. CIR Core Team, "R: A language and environment for statistical computing." R Foundation for Statistical Computing, Vienna, 2022, [Online]. Available: https://www.r-project.org/.
- 40. Burham, K.P., Anderson D.R. Model selection and multimodel inference: a practical information-theoretic approach. Springer-Verlag **2002**, New York
- 41. Symonds, M.R.E. Moussalli, A. A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike's information criterion. *Behav Ecol Sociobiol* **2011**, *65*, 13–21.
- 42. Opdebeeck, C., Martyr, A., Clare, L. Cognitive reserve and cognitive function in healthy older people: a meta-analysis. *Aging Neuropsychol Cog* **2016**, 23(1), 40-60.
- 43. Nelson, M.E., Jester, D.J., Petkus, A. J., Andel, R. Cognitive Reserve, Alzheimer's Neuropathology, and Risk of Dementia: A Systematic Review and Meta-Analysis. *Neuropsychol rev* **2021**, 31(2), 233–250.
- 44. Pucci, V., Guerra, C., Barsi, A., Nucci, M., Mondini, S. How long have you exercised in your life? The effect of motor reserve and current physical activity on cognitive performance. *J Int Neuropsychol Soc* **2023**, 1–7.

45. Siciliano, L., Olivito, G., Urbini, N., Silveri, M.C., Leggio, M. "Mens Sana in Corpore Sano": The Emerging Link of Motor Reserve with Motor and Cognitive Abilities and Compensatory Brain Networks in SCA2 Patients. *Biomedicines* **2022**, *10*(9), 2166.